Searching PAJ
`‘
`
`Page 2 of 2
`
`the examiner's decision of rejection or
`application converted registration]
`
`[Date of final disposal for application]
`
`[Patent number]
`[Date of registration]
`[Numberof appeal against examiner's
`decision of rejection]
`
`[Date of requesting appeal against examiner's
`decision of rejection]
`
`[Date of extinction of right]
`
`AQUESTIVE EXHIBIT 1007 page 2401
`http://www19.ipdl.ncipi.go.jp/PA1/result/detail/main/wAAAxSQhiBAdbYB ESATREE, 10079,;pagss2401
`
`

`

`
`
`Japanese Publication No. 1-151528
`
`CLAIMS
`
`5
`
`1. An agent for accelerating transmucosal absorption of a poorly absorbable drug, wherein the
`agent comprises one or more ether or thioether compoundsof C¢-C;3 aliphatic hydrocarbon and
`
`monosaccharide or disaccharide.
`
`2. The agentof claim1, wherein the ether or thioether compoundofaliphatic hydrocarbon and
`monosaccharide is represented by Formula (1):
`
`10
`
`CHO
`
`0
`
`OH
`
`HO
`
`OH
`
`A-R
`
`ss)
`
`wherein A represents an oxygen atom or sulfur atom; and R represents a Ce-C¢ aliphatic
`hydrocarbon group.
`
`15
`
`3. The agent of claim 1, wherein the ether or thioether compoundofaliphatic hydrocarbon and
`disaccharide is represented by Formula(2):
`
`CH.OH
`
`CH,0OH
`
`Q
`,
`Q
`OH A~R=(2)OH
`
`
`
`
`
`HO
`
`0
`
`OH
`
`oH
`
`wherein A represents an oxygen atom or sulfur atom; and R represents a Ce-Cjg aliphatic
`hydrocarbongroup.
`
`AQUESTIVE EXHIBIT 1007 page 2402
`AQUESTIVE EXHIBIT 1007
`page 2402
`
`

`

`© % H Hi AS BA
`@ A * 4 oF FF (JP)
`© AR at ZB i (A) 1 - 151528
`ae Paes
`—@ASB 81 2E(1989) 6 AB
`@Int.cl,*
`326
`E—7417-—4C
`A 61 K 47/00
`E—7417~4C
`.
`9/02
`Seink Kigk BANK 1 (6H)
`
`GRAN HRQL
`
`FA62— 311680
`OF
`BA #B62(1987)12A 8 A
`@u;
`SSPEOR 1A PRA6ZEO AISA AARAISSRETO | AAMAS 3 FSR
`Bj irsoCHE
`
`Oe 8 4 HH B
`
`cB =
`
`OH FA XBRLRAASH
`GR BA F#t AR id
`
`RAREEMEAREBAHay562—
`19
`HBTRARaay 1 —27
`
`mn
`
`8
`
`&
`
`VE 1 BR RA
`
`1. RHOLK
`
`AUEMRMEOM
`
`
`
`
`
`HO
`
`0
`
`OH
`
`OH
`
`CH,OH
`CHLOH
`Q
`Q
`2. HER KO RD
`OH A~R=(2)OH
`(1) MMM GLO IAME RRM ~ LEO
`RRMKEOS- Frew EL CER Z-F
`ViSWOI AEE TMRPEL TRATES
`
`ORR HE Ry OF HEH IRR RAR He A.
`(2) MOM ERO BRR KR OZ - Fs hE
`LEA LH FMS WHE E-MR(1NCR
`
`(AP, AGREMEIRGAMM EE. RARE
`RGO~ OMAR RILKREL RT)
`I, RUA As AM
`
`(HR LON M SH)
`
`bENSALSHMCASHAMKNORHHI MER
`
`ARMS WR UROL MEM MTS.
`
`OE HG HE TAR HY
`
`(HO IE)
`
`CHO
`
`OH
`
`HO
`
`Q
`
`OH
`
`A-—R
`
`.
`
`—
`
`q)
`
`(RP, AGREATREMRATE, RRR
`
`ME~BOMMARKLKARBE TT)
`
`RRREMESHTSIBRAGNMOMRIL.
`KOE ROL RERATE RS ORRMERYD
`
`EENHELOTAMESSELANTELHNTT
`
`P-FNMIDELTHBENHTWHSe, RMCK
`
`LEMIZARMEL THEO, BHMOECRMEEM
`
`ORMPKSRRAFEL TI. RI RPWRETEK
`
`(1) (OME RIKEN - Few
`
`RECHSIL. SHEMALE EMILE OM
`
`Lite ro Pe OM FR-MA(2TR
`HENSCSHSCHASHAMNKOBAHINAR
`
`Deleon nt, EREVENNM ORE OH
`"MEGA OLE EMR ENS,
`
`—225—-
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2403
`
`page 2403
`
`

`

`19 MF 1-151528 (2)
`
`URronoRRteMlLeesrvHooRRKiz.
`
`OMMURRLKRN2-FeLAaBeE LRT
`
`MRI VBA RH ontTH), AKER TE 1M
`
`L-FRELEWOIMAULERMAPEL TCE
`
`OWA, MORARYP eanReM. cri rs
`
`TEAAMHERHOKNTRARMRANIH RS.
`
`BK FU FRA REKOE MF ahd.
`
`ARUNSUZTACAMRAMRLMOMRE G
`
`CJ. Phere, Sei, 66 (7)
`
`955
`
`(1955);
`
`MELTREMREMALMR,. RALREAM
`
`RMF 38 (2)
`
`67
`
`(1978);
`
`Clin, Res,
`
`CEBZERMERRT SCBA.
`
`25 (3)
`
`386A;
`
`J. Phare, Dyn, 3 24
`
`ARMIZDHUSPMMELTIIALEL- 77
`
`(1980);
`
`Ent, J, Pharo, 2 $08
`
`2 055 - 8486,
`
`$3 4s 55 — 8456;
`
`(1979);
`$F M57 —
`
`ws ra, D-H ee OH- KR, DV K- AL D-
`7na-z, D-ers/s- AL N-VFITFE-KA,
`
`158719,
`
`493 1 0R 53 ~ 177395,
`
`O59 — 176209
`
`D-7FAAbL-A, ERITMMELCHETAE-
`
`¥).
`
`A, eoerr- azar, bean oe rz, FYFRER
`
`LaolLinanmitiz, HMHREMNGLE,
`
`-AL AV PHEW AL ARB. DIR FORE
`
`BROT PPA, NNR BRA SF
`
`na.
`
`.
`
`OKRA ATELOHEC. LVTMAVEST
`
`ARMS SRRMG~ L8OMMBRICKR
`
`HALE RMRREMOMRAMEAa Nts.
`
`HMR CEPMR CEE. MMMM it Fe
`
`(RMA eMRECE GET INAA)
`
`HnvYSeETHE EW,
`
`KRAMAMIS, LIOMRHANHT. KERHD
`
`ERMHNRILKKYOKEM FHV OReNT
`
`RELRKMURMAMRAMERATSIOLCAS.
`
`ERT SMMNKIEKRBE CTI, ALENT LY
`
`(NEA EMRTSLONDFR)
`
`Mi nT EN RIPEN Sah, FEM, D7
`
`ARAIIRMAMEL CURCOMMERRRS ~ 18
`
`FYUAL, RFP YA,
`
`by P Ya, TEP YAN,
`
`NET UNL ADIF YN, 2-4 FHNEY
`
`(Ab. ARRAMFEREMRAF Ee. RRR
`
`WM, 2-kREFNAMY ER, PH-LEHNAT A,
`
`R-XLFNUNAT EM, 2-LEMADENM, 2
`
`RE ~HOMMRMRLKREE RTICHRHEA
`SiS Maowe eer,
`
`LFNM/ HN, 2-LFNF YM, 2-LERYD
`
`ZCHAHOUPEL YES RORKHMEL TIO F
`
`ALMMRITE NS,
`
`n~t7¢N-~Pr-D-SFHIAKG/ YE,
`
`2 a
`
`—-RFNNKYA-A2,P-DN-FABEF
`v
`yF¥,
`
`a-t7FN-A-N-F4*7nrIK F/T,
`
`n-n7FFHR-B-D-F4*7F nae R/YEF,
`
`o—-F79NR-B-D-ePaHbeE Fs YEF
`
`ZTAGLOGMOMURREKREN(F 4 )zr-
`
`FORMER. ALTHRBUR. ttn
`
`RUB. RHR. OMMM. RHR. ANRME
`
`MU CHORHBORMMREAL IMA, eA tTH
`
`APU FA-ERREKME LOS TL HT:
`
`Sb. MHINGNMBROMMRR(KREM(F
`
`A)E-FUMISERMRM ME Ade Ee
`towWOH1, FREARCELENTAL.,
`
`ARUN CRMRELMREMGENLRWELT
`
`YF UML UIN-ISENAIEM, PHN KRY
`NFM 2-KRDPENF UNM, 2,4,4- Fb VS
`
`FANLIFNMENTMRERDAMNE OO KITG
`
`nb. RX. TRAREKRBEL TI, ALE
`
`Cis~ 28 -N& HEM, LOHR FST ANKE TAN,
`
`tAANM, V/VARF ORY ENS,
`
`ERMMEMUARILKBELOT-FAELS
`
`RTE - Fase wohee, FRRO)RY (2)
`
`CH,OH
`
`OH
`
`A-R
`
`a)
`
`HO
`
`.
`CH,OH
`0
`
`OH
`
`HO
`
`-
`
`OH
`
`OH
`
`.
`CH,OH
`
`OH
`
`OH
`
`—226—
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2404
`
`page 2404
`
`

`

`It, ERKEMBOH. MMAMEDRETSERIE
`
`1h RHCH. ALKKREM. HRM A
`
`AMEDM. heer. WAM. AP ene
`AM. AREA. PAM RRA. RAR
`
`RAM. EDFONM PL ENOMERewrse
`at ad,
`
`ARPA YL FOP,
`
`13 fF 1-151528 (3)
`7avtVWAY
`
`YENTEST VIL OMKEDM GE CAE
`ns,
`
`mE YAEL TIS, HLL vayr,. 7
`
`VIALE RYT VEY, FOFVIU TZ,
`
`JeKbouvritnnty, aataborr,
`
`UREN ELIZ, HLL TIOFT Vs —-awe
`
`MKMAMAAE Yr. RKBRRDEY, any t
`
`Won, MABSOMML LI. Has Far
`
`A SPRF ALOMAR MMEML, bre YH
`
`ZY. WAL YY BOB ONS.
`MBM ELT. AzLS-Paxrazvgeyn,
`
`PUYTRM=aAs/SF-FOMAMRKAM. Fo7
`
`TRYNM, CG-HsHATETYr, AEE
`
`F/U-NM, DY KOA YLMMOMS Hh
`
`~bL Fue qyr F7SMEY ry, FRY
`
`AMRet RY Sr ea cas.
`WREMMEL CE, WARE IG. «
`SYYYV FEY YY, POE YY, PY
`
`MEY, LO PRADEEP HUME UMBTEK
`
`3.
`
`Hh7 vA ¥ -AM,. EROS MMEL TI.
`
`CRD NI YY YL, VODYYN YT, TERY
`
`ALPDES YT —-bFOMS HABM GS CRIT
`
`VY WNHRRY YY RNR YY TBD
`qt
`
`YUVCMREBM ec 7reyr, e770 4
`
`nS. PRMRRMMEL TI, HAH. Rib
`
`KEMADK FET SART HONS. KRAMER
`
`YY RIARLE YL TP ater, TTY
`
`MAMET, MAPCAs EAM,
`
`PY RITES VY YL, EPTUAY YS ENE
`
`FRIMATEUMRYENS, EWFINMALE
`
`TT OARYUTMRERM, ALVTE tyr,
`s
`
`CTH, ALTE V For, FeV Yr. 7
`
`4 v¥P-BH*e
`
`TRF #H. AY I-TLOY.,
`YE MET ENS,
`,
`EERWEARHCAATISEOOIATA
`DTETCRGUELRMENEXETAS,
`
`R. ARPOUMRNRRAMELERMLAG
`
`RRRENHRERF TSO ATR Sa, HE
`
`LCORFORMSMEL THC MARE.
`
`hw E7TYt-a(eP noma) rei. AD
`
`MYOMhn, RIN eKRBM. Teen
`
`{C. PMMU FLORAL REN RIT EH,
`SLIT EAT EMMMES SRE MBE L
`THIF YT GORIT ENS. BOM EL TAME
`
`LIS - NW MMK, FVD SHHRMO
`bn, BRMOBACIT FET TA, here
`
`KANORKBBRERRANE MeO RAR EM
`
`BL RFF. SFM EN OK KR, ANKE D YS
`
`MIce7T, AMRINKRS RE RHOBA,
`
`Freenwa-A(CMC)BHDOE Mv ono, 7
`
`RO MNOMM ELE EDEORGO-MCRE
`
`AMAMNIBS IIE KROL FOREN e AG
`
`tne, MMS MAIC L COL] ~ 201% ae EF
`
`AL, A+FMeENMD- AL KY KSTAK TY Y,
`
`EUG. ROEHL CI0.5~5HRYCHS.
`
`KYR SUNT NRI- LEHNER OMY ON, Rid,
`
`KRW RHR REAM Ee Me em SH
`
`MW. MRM OUCH Ae ao - A,
`
`MiMi. BOM, BM. 74a,
`
`LTS OWN, RM, MN, BAR Hea
`
`ASM, BH ETSMBE BEC. RHR
`RLRLLMLH OM eSAeLHSoeaea
`
`B. WMLEBMETEMGOEMELTERER
`G6 ~2R0OMMRMETF VD YY NTRS AM, HZ
`
`EFESILOCAHKAFOREMOE Foe ET
`
`OK ARKH O- AL SFM END REARS IG
`SeMRMO GN’, KITV -MMOBS EL
`MUM EL TYP a av TIA OLSIL BAUR
`
`Moons,
`INHbHOGNBDETATLHRRSERMI.
`
`WTAE se SME VFI TY KH
`
`RtibnAtwS SMR EatCRHPTSre
`
`—227—-
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2405
`
`page 2405
`
`

`

`33M) F1-151528 (4)
`
`50 U
`
`eg
`
`HOR, EORSRERMOMCRC. DRRA
`
`HAS
`
`M491 AH MIR I0.01 ~ 200g ke
`MHL + soe se Ler,
`
`4vyn4r
`
`.
`
`a-*7¢FN-B-D-FABKFS YF
`
`(Rw A)
`
`KEAKRUORMRAMERA LAMM ORK
`
`He RHWME WITS,
`
`RW
`
`e779Ry
`
`o-F7YU-P-D-vabtersee
`
`BiH 4
`
`500g
`
`MMe Aer.
`
`WAAR
`lt wes 9
`O. lef
`
`ERNRGARCHRARE(A TIA 7 -INOF
`
`PAFVTS -& WAS
`
`1 hts 9
`
`ERNAMS CHM EANL ee,
`BH Ww 2
`
`J0eg
`
`14700g
`
`2000u8
`
`e779F rr UT!A
`
`250mg
`
`a- at 7¢n-A-D-FAeF HIE FSTE
`
`Ne nao-%
`
`FvTrv7TVA-HWMFbhIITDA
`
`1000¢
`
`15008
`
`1500¢
`
`20mg
`
`Treyvyyrrry7a
`
`25008
`
`eros 7FarUHAKNH AHAB
`
`2-LFN- NEY N-O,A-D-
`tr7naersye
`
`QPAFTVTSL-n W-35
`
`1 eis 9
`
`LEMS AS CHM EARNER.
`
`A0we
`
`1710ng
`
`20000¢
`
`ERFuoe YF Ure AeKhOK- KATH eH |b
`
`va9uzr—-nr 6000
`
`tas
`
`300ng
`
`30eg
`
`1000u¢
`
`LERGASCHMBEMNRM EARLE.
`
`RHAS
`
`e7UEFAEF
`
`Ft ow IaEFSY K(OTG)E ENE HI00M
`
`18M ff &B
`
`(499, 1H/V% ). 50uM (ADE. SH/V 9%), 10aM (490.3
`
`n—-F777N-B-D-7AbhERSYSY
`
`2m RH
`
`80% Mo
`
`7477S - wm WH 95
`
`LEMGASTHNHERNUR,
`mH AG
`
`e7eFrEF
`
`“18 oh ft
`
`s-F7YR-B-D-eHhE DS YF
`1 hae
`Bi A RB
`
`QAFIT SL — w W~35
`
`LENS CHM ERLE,
`wHWMI~ 9
`
`KS OAMEBML CHMMELL.
`Bi ALI~ 14
`
`BAATLARMEL TINT tH 4-A8-D-
`FF TNHIKFSYF(NTG)& En H1000M
`
`(492, 9W/¥95 ), 500M (491, 5H/V% Ow Me I
`
`LTBMMELK,
`WIS ~ 17
`
`,
`
`MAA TEAM LT2Z -2tareen-
`a,8B-D-FAAKFSEY F(D-OG)E ENG
`
`100M (492, 9K/¥9% ), 500M (491.54/V%), 350
`
`M (1 OW/V% or MI ML THAME LK.
`
`p74 9 FRR BAM KOON LL, o-
`
`MH HAAB~ 21
`
`QFHM-B-N-FnMIEF/SYE(N-OG)E
`
`ENE N100—M (492,90 /9% ), S0RM (ADT, SW/Y
`
`%). 200M (490, 6H /1% Do Reis ML Te
`ele.
`
`MAATEM MILT 779 R-A-D-
`PUEEFSEF(LM)E ENE N500M (92,6
`W/V%),
`10mM (490. 5H/V% ),
`5 oM (490, 26W/¥
`%)S 250M (490. 19W/ V6 om eS LOC i ik
`
`MeANO~ 12
`
`BHATLEARIZGL Ta-t IF H~A-D-
`
`MeL.
`
`eH M22
`
`—228—
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2406
`
`page 2406
`
`

`

`e7eEPEE
`
`18M ff m%
`
`Fnwaksesve
`
`73M F 1-151528 (5)
`2 Mm AB
`
`n-ne Yn B-D-FHsaeasvFk
`2 MH i
`
`DAFITY —- mw W355
`
`80m ft
`
`ERMSHSCHMEARLEK.
`
`17 23
`
`*7e72F
`
`DAFVTS -& W395
`
`80m fi RB
`
`(LRA OAMD CHM EBAALA.
`
`77 A426
`
`£7UeFEF
`
`9K OTK eaw-B-N-
`FwszaegsyvK
`
`18 1h ft &
`
`YARVT I -W WH 35
`
`18 3 OB
`
`.
`2 M ft
`
`ROM Ht RB
`
`n- AY NW -B-D-FATFAIEF/SYYE
`2H RH
`
`QAFVITS ~ Ww W395
`
`801 ft a5
`
`LEMONS CUMEMNLK,
`AL OAR IR EL. ENE BL OR UU OR i te a
`mre.
`
`ERMOASCHMERMLE.
`
`< THM LR >
`
`Se HZ
`
`e£7Ue73F
`18 i &
`n= PII PENH B-D-TMBEDIYFE
`2am
`
`SRB ir bw Tle. Wislar KM HF 7 + (240
`~ WORM EME MLM CH 6 cot RM
`Brel tor.
`
`(1) REMT ~UOHMMREN MHL LTH
`
`JAFVTS—~ wm W- 3S
`
`80M ft AB
`
`TAY vB CHK 100RL BRM It Ry
`
`LRMSHeCHMERRLE,
`
`2 2S
`
`“4707 F
`
`Y-rFSEAnNKYEN-aH-D—
`
`EFUMELTKAENMMEERTASG-AAK
`
`RYT MALEAY(CE IOI eM L. 16m Ml
`
`18m
`
`BML EAE THN FOI EDK
`
`M: 520ne) IDE 0@RLR. BREWI-~ SHE
`n-OG 100eM|51.6412,0|2594,94225.9
`(600g /ke)
`RT.
`OTG 1000M|45.34 5.7|2692.04 189.3
`(2) BHA T(n-OG, H2.9N/V%), BH M1IN(O
`
`TEIEE
`
`223,64 95,7
`
`
`
`Mv - 7AKM 25004 91254 RFR. MSM
`KO AEOF MIC HR ih & TPO mhpe-aaksey7
`RHEE YAM EMHKEMIE(E X: 49000, F
`
`TG. O3.1W/VY OR AMREAM HE LPH
`
`74M RBM RM KIe 7 FE KF
`
`luv arit rv i.bst H7GML,
`
`16
`
`HM MALE KT EAE FI He WRF DG 7 I
`
`NAKHV-SARLAO SARE KM250e4 9
`
`1254 0 FR, MPO E OOF MIC Rh IT,
`fhe TE FERRERS ET eA YT AME
`
`sab, AT CC 6623)
`~ + - FA ADE Cbacitlus
`RENDER.
`tEnvAnm PALF MMA YU
`
`Cyt RAK, SBREMIRERT,
`
`Teawdys
`
`-
`
`(8 ag/ke)
`
`a-OG 1000M
`OTG 1000M
`
`(3) MHAS., GRUMMMEL TET ETEK
`
`ISM RB. TAF YTS — wm W-35(82M BB)
`OMAR E DREW EOE. NL MRD
`cE CEMAAL ET T7TIMOMMIERFL., UF
`
`ARAB VDLAMERHAR hb MMORBe
`fon.BREMGBERT.
`
`LL RMA tb BM OT HERR Ei Ht
`
`EBROCRHOKUBRMILENRMREATS
`LewMa ota,
`
`4. BRO MM fe OF
`
`~229—
`
`AQUESTIVE EXHIBIT 1007 page 2407
`AQUESTIVE EXHIBIT 1007
`page 2407
`
`

`

`M1 ~ GCHERRRBRIEKTSRHOhHD AM
`
`OKMBRLERT TITAS.
`i
`
`.
`(Hk £)
`
`ho M
`
`©
`
`£
`
`A
`
`A
`
`kKMRBRLERRSU
`
`fet Mm
`
`HH
`
`ft
`
`34H 1-151528 (6)
`
`a1 B
`
`* 2
`
`w
`
`uo
`
`I
`S
`a
`¥
`x
`ao
`=
`a
`
`
`
`n0G
`O 100eM
`A 50
`oO 2
`@ centro!
`
`
`
`Time tmin!
`
`3
`\
`a.
`~
`4.
`a
`+
`z
`
`
`
`
`
`
`OTG
`© 1000M
`4 50
`#10
`@ control
`
`
`
`0
`
`30
`
`129
`
`90
`60
`Tima imin)
`
`.
`
`*
`
`4
`
`* 3
`
`
`
`
`*
`b-OG
`3 ‘
`& 1000M
`
`3
`O 50
`3
`B 35
`| @ control
`
`
`a =
`
`4
`
`
`
`HTG
`© 100M
`A 50
`@ control
`
`ihPW(48/o8)
`
`
`
`0
`
`390
`
`-4
`80
`60
`Time (min)
`
`120
`
`0
`
`0
`
`30
`
`$0
`60
`Time (min)
`
`129
`
`.
`
`mh PRM (ueet)
`_° a:
`
`6
`
`8
`; 2
`x
`Be
`2°
`8
`
`,
`
`=?
`
`8
`
`a
`a8
`5
`a 2
`°
`
`oz
`
`:
`Cc
`a
`@pag Or =z
`Sn wn
`2 nos
`3 =x
`&
`
`.
`ifn op ia m (4e/at)
`8
`¢
`8
`
`s
`
`8
`
`Pe
`
`a
`a
`
`
`
`}o4)u009@ ost
`
`
`—230-—
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2408
`
`page 2408
`
`

`

`
`
`(21) International Application Number: PCT/US91/04104|(74) Agents : BARAN,Robert, J. et al.; Allergan, Inc., 2525 Du-
`
`pont Drive, Post Office Box
`19534,
`Irvine, CA
`(22) International Filing Date:
`11 June 1991 (11.06.91)
`92713-9534 (US).
`
`(30) Priority data:
`0
`
`15 June 1990 (15.06.90)
`
`US
`
`(71) Applicant: ALLERGAN, INC. [US/US]; 2525 Dupont
`Drive, Post Office Box 19534, Irvine, CA 92713-9534
`S).
`(72) Inventors: JOSHI, Abhay ; 120 Monroe, Irvine, CA 92720
`(US). DING, Shulin ; 14641 Fir Avenue, Irvine, CA
`92714 (US). HIMMELSTEIN, Kenneth, James ; 217
`Gilbert Avenue, Pearl River, NY 10965 (US).
`
`(81) Designated States: AT (European patent), AU, BB, BE
`(European patent), BF (OAPI patent), BG, BJ (OAPI
`patent), BR, CA, CF (OAPIpatent), CG (OAPIpatent),
`CH (European patent), CI (OAPI patent), CM (OAPI
`patent), DE (European patent), DK (European patent),
`ES (European patent), FI, FR (European patent), GA
`(OAPI patent), GB (European patent), GN (OAPI pa-
`tent), GR (European patent), HU, IT (European patent),
`JP, KP, KR, LK, LU (European patent), MC, MG, ML
`(OAPI patent), MR (OAPI patent), MW, NL (European
`patent), NO, PL, RO, SD, SE (European patent), SN
`(OAPIpatent), SU, TD (OAPI patent), TG (OAPI pa-
`tent).
`
`Published
`With international search report.
`
`
`
`(54) Title: REVERSIBLE GELATION COMPOSITIONS AND METHODS OF USE
`
`(57) Abstract
`Reversibly gelling aqueous compositions are disclosed which undergo significant changes in viscosity in response to sub-
`stantially simultaneous changes in both temperature and pH. The compositions are formed ofrelatively low concentrations of a
`stable combination ofat least one pH-sensitive reversibly gelling polymer andat least one temperature-sensitive reversibly gelling
`polymer. The compositions can be formulated to exhibit a sol-gel transition over a wide range of conditions and viscosities and
`may be modified to incorporate a pharmaceutical compoundforutilization as droppable or injectable drug delivery systems
`
`WORLD INTELLECTUAL PROPERTY ORGANIZATION
`PCT
`International Bureau
`INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`(51) International Patent Classification 5 :
`(11) International Publication Number:
`WO 91/19481
`A61K 9/107
`(43) International Publication Date:
`26 December1991 (26.12.91)
`
`which will gel following administration to a physiological system for the sustained delivery of such pharmaceutical compounds,
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2409
`
`page 2409
`
`

`

`FOR THE PURPOSES OF INFORMATION ONLY
`
`Codes used to identify States party to the PCT on the front pages of pamphlets publishing international
`applications under the PCT.
`
`United States of America
`
`Spain
`Finland
`France
`Gabon
`United Kingdom
`Guinea
`Greece
`Hungary
`Italy
`Japan
`Democratic People’s Republic
`of Korea
`Republice of Korca
`Liechtenstein
`Sri Lanka
`Luxembourg
`Monaco
`
`Austria
`Australia
`Barbados
`Belgium
`Burkina Faso
`Bulgaria
`Benin
`Brazi!
`Canada
`Central African Republic
`Congo
`Swiwerland
`Céte dIvoire
`Cameroon
`Czechoslovakia
`Germany
`Denmark
`
`Madagascar
`Mali
`Mongolia
`Mauritania
`Malawi
`Netherlands
`Norway
`Poland
`Romania
`Sudan
`Swedea
`Senegal
`Sovict Union
`Chad
`Togo
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2410
`
`page 2410
`
`

`

`WO 91/19481
`
`1
`
`PCT/US91/04104
`
`REVERSIBLE GELATION COMPOSITIONS AND METHODS OF USE
`
`FIELD OF THE INVENTION
`
`The present invention relates in general to macromolecular polymer
`
`mixtures exhibiting reversible gelation properties. More particularly,
`
`the present invention is directed to aqueous compositions that revers-—
`
`ibly gel in response to simultaneous variations in at least two physical
`
`parameters
`
`such as
`
`temperature and pH or
`
`ionic strength.
`
`These
`
`compositions can be designed to reversibly gel at varying viscosities
`
`10
`
`over a relatively wide range of conditions, making them particularly
`
`suitable for use as droppable, oral, or injectable drug delivery systems
`for the sustained and controlled delivery of pharmaceutical medicaments
`
`and diagnostic agents.
`
`15
`
`BACKGROUND OF THE INVENTION
`
`Various
`
`approaches
`
`to the production of
`
`reversibly gelling
`
`solutions have been developed over the years. Principal efforts have
`
`been devoted to the development of gelatinous drug delivery systems for
`
`20
`
`topical
`and subcutaneous applications and, more
`recently,
`for
`the
`administration of ophthalmic drugs to the eye.
`In general, sustained
`release drug delivery systems incorporate pharmaceutical agents in solid
`
`or semi-solid vehicles which are applied to or implanted under the skin
`
`of a patient by medical personnel. Additionally, unlike conventional
`
`drug delivery systems, ocular drug delivery systems also must address
`
`25
`
`the additional problem of drug loss through the lacrimal drainage system
`
`as well as the needs of patient comfort and ease of administration.
`
`Early approaches to the solution of the problems associated with
`
`ocular drug delivery systems utilized semi-solid ointments or gels
`
`applied directly to the conjunctiva or cul-de-sac of the eye to retain
`
`30
`
`the pharmaceutical agents contained therein on the ocular surface
`
`against such physiological factors as
`
`tear turnover,
`
`tear drainage,
`
`blinking, and other mechanical losses.
`
`For example, U.S. Patents Nos.
`
`3,944,427 and 3,700,451 disclose gelatinous drug delivery compositions
`
`containing agar, xanthine gum, and carob gum in liquid mediums in order
`
`35
`
`to enhance their residence time upon the skin or mucosae and the
`
`resultant bioavailability of the medicinal products contained therein.
`
`Similarly, European Patent Application No. 0 300 888 Al, filed July 18,
`
`1988, recently disclosed the use of rhamsan gum to thicken ophthalmic
`
`compositions for droppable and topical application.
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2411
`
`page 2411
`
`

`

`WO 91/19481
`
`PCT/US91/04104
`
`Though effective at
`
`tnereasing drug retention times,
`
`lack of
`
`patient acceptability remains as a significant drawback to the use of
`such known viscous drug delivery compositions in the eye. Many patients
`experience difficulty in applying the appropriate amount of
`such
`compounds to the eye and resist the unpleasant side effects of eyelid
`crusting and vision blurring. As a result,
`these compounds may only be
`suitable for use in the evening or during non-active hours.
`A known alternative approach to these problems was the use of a
`formulation which is liquid at room temperature but which forms a semi~
`solid when warmed to body temperature.
`Such a thermally triggered
`system is disclosed in U.S. Patent No. 4,474,751, where an aqueous drug
`delivery system that forms a semi-solid "gel" at body temperature is
`formed
`from proprietary polymers
`known
`as
`“Tetronic®*"
`polyols.
`Generally speaking, these compositions are formed from approximately 10%
`to 50% of the specific polymers in an aqueous base.
`By adjusting the
`pH of these drug delivery systems through the addition of buffering
`agents,
`the gelling transition temperature can be raised to physiologi-
`cal temperatures on the order of 35°C.
`Similar drug delivery systems which can be injected subcutaneously
`or intramuscularly are disclosed in United States Patent No. 4,474,752.
`These compounds also contain from 10% to 50% by weight Tetronic®
`polymers and gel at temperatures from about 30° to 10°C.
`
`A thermal setting gel drug delivery system is also described in
`U.S. Patent No. 4,188,373, utilizing "“Pluronic® polyols"
`as
`the
`thermally gelling polymer. Adjusting the concentration of the polymer
`gives the desired “sol-gel" transition temperature. However, producing
`a compound which sets at physiologically useful
`temperature ranges
`limits the available viscosity of the gelled product.
`Alternatively, it has been proposed to utilize formulations which
`in response to changes
`in pH as drug delivery vehicles.
`By
`gel
`carefully controlling the pH of such mixtures, a solution which forms
`a gel upon mixing with aqueous
`tear
`fluid could theoretically be
`produced. However, it is believed that the relatively high buffering
`capacity of such pH responsive compositions can lead to slow gelling,
`irritation and discomfort in patient eyes.
`the
`Though successful at achieving increased drug retention times,
`relatively high polymer concentrations required by such formulations
`undesirably increase both the buffering capacity and the amount of
`thermal energy necessary to induce gelation of the compounds which may
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2412
`
`page 2412
`
`

`

`WO 91/19481
`
`—3-
`
`PCT/US91/04104
`
`lead to irritation and discomfort when used in the eye. What is more,
`the high polymer concentrations also contribute to unacceptably high
`product costs and generally slow the gelling process as well,
`leading
`to migration of the compounds from the site of application or injection.
`Accordingly, it is a principal object of the present invention to
`provide a reversibly gelling polymer solution having significantly lower
`
`polymer concentrations than has previously been attainable by the prior
`
`art in order to reduce both the buffering and thermal capacities of the
`
`solution to ensure its rapid and complete transition from liquid to gel
`
`10
`
`upon application to a physiological system such as an oral dosage,
`
`the
`
`surface of the eye, or an injectable drug depot.
`
`It is a further object of the present
`
`invention to provide a
`
`reversibly gelling solution which can be utilized as a drug delivery
`
`vehicle or wetting solution that can easily be administered by a patient
`
`15
`
`in the form of a freely flowing liquid or drops which gel
`
`immediately
`
`following administration with minimal side effects,
`
`thereby providing
`
`ready pacient control of drug dosage and improved patient acceptability.
`
`It is a further object of the present invention to provide an oral
`
`dosage, drop-instillable,
`
`injectable or other depot form drug delivery
`
`20
`
`vehicle which will prolong drug contact
`
`time for
`
`improved bioavail-
`
`ability and for sustained drug release.
`
`SUMMARY OF THE INVENTION
`
`Generally stated,
`
`the present invention accomplishes the above-—
`
`25
`
`described objectives by providing aqueous compositions that reversibly
`
`gel in response to substantially simultaneous variations in at least two
`
`physical parameters such as temperature, pH, or ionic strength. What
`
`is more,
`
`the compositions of the present invention can be tailored to
`
`exhibit a specific sol-gel transition over predetermined temperature and
`
`30
`
`pH ranges to make the compositions particularly well suited for use as
`
`drop-instillable aqueous wetting agents and drug delivery systems, as
`
`well as for use as injectable sustained release drug delivery systems.
`More particularly,
`it has been surprisingly discovered that
`
`superior reversibly gelling compositions can be produced from unusually
`
`35
`
`low concentrations of uniquely synergistic polymer systems which stably
`
`exist in aqueous solutions.
`
`In contrast to prior art gelation systems
`
`that rely on only a single triggering mechanism which may be either
`
`changes in pH,
`
`ionic strength, or changes in temperature,
`
`the compo-
`
`sitions of the present
`
`invention reversibly gel
`
`in response to sub-
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2413
`
`page 2413
`
`

`

`WO 91/19481
`
`PCT/US91/04104
`
`—4—
`and pH over
`in both temperature
`changes
`stantially simultaneous
`predetermined ranges. What is more,
`the synergistic gelation action of
`the compositions of the present
`invention produces rapid and complete
`viscosity changes of an order of magnitude without the undesirable side
`effects associated with the high polymer concentration, single gelation
`mechanism compositions of the prior art.
`invention
`These properties make the compositions of the Present
`particularly well suited for uses as topically applied lubricants and
`wetting agents as well as for drug delivery vehicles where sustained and
`controlled delivery of bioactive agents
`is desired.
`For example,
`wetting agents, ocular drug delivery vehicles, oral and injectable drug
`delivery compositions can be produced in accordance with the teachings
`of the present invention which exhibit steady state flow characteristics
`at or near room temperature and a pH range of 2.5 to 6.5, yet almost
`instantaneously transform to highly visco-elastic gels when exposed to
`physiological conditions of pH and temperature on the order of pH 7.4
`and 37°C.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`Exemplary compositions are formed in accordance with the teachings
`of the present
`invention from aqueous solutions containing effective
`concentrations of a stable physical admixture or combination of at least
`one thermally~sensitive gelling polymer and at least one pH-sensitive
`gelling polymer. Thermally-sensitive gelling polymers for practicing
`the present
`invention can be selected from the group including alkyl
`cellulose, hydroxyalkyl cellulose, cellulosic ethers, Pluronic® polymers
`and Tetronic® polymers, with methylcellulose being particularly
`preferred.
`Exemplary pH-triggered gelling polymers
`that produce
`thickening at increased pH are preferably acidic polymers such as those
`containing carboxyl groups.
`Those skilled in the art will appreciate
`that small amounts of crosslinking agents such as divinyl benzene,
`divinyl glycol and polyalkenyl polyethers will facilitate the formation
`of three dimensional polymer network structures in the resultant cross—
`linked polyacrylates. Carboxy vinyl linear or branched or crosslinked
`polymers of the monomers, such as methacrylic acid, ethacrylic acid, f-
`methylacrylic acid, cis-a-methylcrotonic acid,
`trans-a-methylcrotonic
`acid, a-butylcrotonic acid, a-phenylacrylic acid, a-benzylacrylic acid,
`a~cyclohexylacrylic acid, and the like are examples of such acidic pH-
`sensitive gelling polymers. Conversely, where thickening is desired at
`decreased pH, polymers containing weakly basic pendant groups such as
`poly-N-N-dimethylaminoethylmethacrylate may be employed.
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2414
`
`page 2414
`
`

`

`WO 91/19481
`
`PCT/US91/04104
`
`~5-
`In contrast to the relatively high polymer concentrations required
`by the individually triggered prior art compositions (on the order of
`10% or more by weight),
`the reversibly gelling compositions of
`the
`present invention preferably contain only approximately 0.25% to 5% by
`weight
`thermally-sensitive gelling polymer and only 0.1% to 0.5% by
`weight pH-sensitive gelling polymer. This substantially lower polymer
`concentration significantly reduces
`the
`amount of
`thermal
`energy
`required to induce gelation as well as reducing the buffering capacity
`
`of
`
`the compositions of
`
`the present
`
`invention, making them markedly
`
`10
`
`superior topical wetting agents and drug delivery compounds.
`
`When
`
`utilized in the ocular milieu,
`
`the compositions of the present invention
`
`eliminate the discomfort, vision blurring and crusting produced by the
`
`known prior art compositions yet produce rapid conformational changes
`
`to high viscosity.
`
`However,
`
`it is contemplated as being within the scope of
`
`the
`
`invention to utilize thermally-sensitive gelling polymer
`present
`concentrations ranging from approximately 0.1% to 30% by weight and pH-
`
`sensitive gelling polymer concentrations ranging from approximately
`
`0.01% to 10% by weight. As discussed in detail below,
`
`these relatively
`
`20
`
`broader polymer concentration ranges increase the scope of the available
`
`viscosities and sol-gel transition temperatures that may be produced in
`
`accordance with the teachings of the present invention. Thus, viscosi-~
`
`ties ranging from 200 to approximately 1 million cP at sol-gel transi-
`
`tion temperatures ranging from 0°C to 60°C can be attained with the
`
`25
`
`present
`
`invention. Nonetheless,
`
`for ophthalmic uses,
`
`the previously
`
`described polymer concentration ranges are preferred.
`
`For use as drug delivery vehicles,
`
`the aqueous compositions of the
`
`a
`invention can be modified through the incorporation of
`present
`suitable pharmaceutical medicament or diagnostic compound in a concen-
`tration ranging from approximately 0.0001% to 50% by weight. As those
`
`30
`
`skilled in the art will appreciate, when compatible medicaments and/or
`diagnostic compounds are incorporated into the aqueous compositions of
`the present
`invention,
`the drugs will also be incorporated into the
`
`gelling matrix following delivery to the target site. As a result,
`
`the
`
`35
`
`drug containing visco-elastic gel will reside at the applied location,
`
`thereby prolonging the retention and delivery of the incorporated drug.
`
`Similarly,
`
`fine suspensions of solid drug compositions or particulate
`
`drug containing delivery systems may also be incorporated into the
`
`reversibly gelling compositions of the present
`
`invention.
`
`Injection
`
`AQUESTIVE EXHIBIT 1007
`page 2415
`AQUESTIVE EXHIBIT 1007 page 2415
`
`

`

`PCT/US91/04104
`-6-
`WO 91/19481
`topical delivery by drop
`into subcutaneous drug delivery depots or
`installation of the solutions will then position such delivery systems
`at
`the site of choice for sustained bioavailability.
`This enhanced
`bioavailability and improved duration of action may lead to overall
`lower drug dosages being required with resultant improved side effect
`profiles.
`:
`Modifications to the viscosity ranges, pH ranges and temperatures
`at which the sol-gel
`transition takes place can be produced in the
`compositions of the present invention by varying the polymer concentra-
`tions as well as through the incorporation of small amounts of univalent
`or divalent salt. Typically,
`the addition of small quantities of salt
`giving a salt-to-combined polymer ratio up to 0.5 and preferably on the
`order of 0.045 to 0.075 will decrease the viscosity of the composition
`in the ungelled state if desired. Alternatively, it is contemplated as
`being within the scope of the present
`invention to incorporate up to
`approximately 0.2% to 0.9% by weight salt.
`Further objects and advantages of the reversibly gelling composi-
`tions of
`the present
`invention,
`as well as
`a better understanding
`thereof, will be afforded to those skilled in the art from a consider-
`ation of
`the following detailed explanation of. preferred exemplary
`embodiments thereof. Reference will be made to the appended sheets of
`drawings which will now be first described briefly.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`FIG.
`1
`is a graphical
`illustration showing the viscosity of a
`Methocel/Carbopol
`(Carbopol concentration fixed at 0.3% by weight)
`mixture as a function of
`the concentration of a Methocel at
`room
`temperature and pH 4.0 Carbopol;
`FIG.
`2 is a graphical
`illustration showing the viscosity of a
`Methocel/Carbopol
`(Carbopol concentration fixed at 0.3% by weight)
`mixture as a function of the concentration of a Methocel at 37°C and pH
`7.4 Carbopol;
`is a graphical illustration showing the viscosity of a
`FIG.
`3
`Methocel (1%)/Carbopol
`(0.3%) mixture as a function of salt concentra-
`tion at room temperature and pH 4.0;
`FIG. 4 is a graphical
`illustration showing the viscosity of a
`Methocel
`(1%)/Carbopol
`(0.3%) mixture as a function of salt concentra-
`tion at 37°C and pH 7.4;
`
`AQUESTIVE EXHIBIT 1007
`
`AQUESTIVE EXHIBIT 1007 page 2416
`
`page 2416
`
`

`

`WO 91/19481
`
`-7~
`is a graphical illustration showing the viscosity of a
`5
`FIG.
`Pluronic®/Carbopol
`(Carbopol concentration fixed at 0.3% by weight)
`mixture as
`a
`function of
`the concentration of Pluronic® at
`room
`
`PCT/US91/04104
`
`temperature and pH 5.0 Carbopol;
`FIG.
`6
`is a graphical
`illustration showing the viscosity of a
`Pluronic®/Carbopol
`(Carbopol concentration fixed at 0.3% by weight)
`mixture as a function of the concentration of Pluronic® at 37°C and pH
`7.4 Carbopol;
`
`illustration showing the viscosity of a
`is a graphical
`7
`FIG.
`Tetronic®/Carbopol
`(Carbopol concentration fixed at 0.3% by weight)
`mixture as a function of the Tetronic® concentration at room temperature
`and pH 5.0 Carbopol; and
`FIG.
`8
`is a graphical illustration showing the viscosity of a
`Tetronic®/Carbopol
`(Carbopol concentration fixed at 0.3% by weight)
`mixture as a function of the Tetronic® concentration at 37°C and pH 7.4
`Carbopol.
`
`DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
`the present
`The
`reversibly gelling aqueous
`compositions of
`invention are primarily intended for use as drop instillable, oral and
`injectable drug delivery vehicles as well as
`for
`topically applied
`lubricants, wetting agents
`and cleaning agents.
`Accordingly,
`the
`preferred exemplary embodiments of the present invention exhibit good,
`usable flow characteristics at
`room temperature, yet rapidly gel
`to
`highly visco-elastic compounds exhibiting viscosities several orders of
`magnitude greater at physiological
`temperatures and pH.
`Thus,
`the
`preferred exemplary embodiments
`exhibit
`significant
`increases
`in
`viscosity in response to substantially simultaneous upshifts in both
`temperature and pH to those conditions encountered in the ocular milieu
`
`those skilled
`or at typical injectable drug delivery sites. However,
`in the art will appreciate that alternative compositions which gel
`in
`response to simultaneous increases in temperature and decreases in pH
`or the converse may also be produced in accordance with the teachings
`of
`the present
`invention where desired.
`Similarly,
`alternative
`compositions which gel at
`temperatures significantly above or below
`those encountered in physiological systems or which exhibit markedly
`different viscosities relative to those of the pre